Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/12/2009Meridian Bioscience Reports Record Fiscal 2009 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2009 net sales of $42.5 million and $148.3 million, respectively, increases of 16% and 6%, respectively, over the same periods of the prior fiscal year; reported recor... 
 Printer Friendly Version
9/30/2009Meridian Bioscience Europe Announces Agreement to Distribute Test For GI Disease
CINCINNATI--(BUSINESS WIRE)--Sep. 30, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced today that Meridian Bioscience Europe srl, Milan, Italy has signed an agreement with BÜHLMANN Laboratories AG, Schönenbuch, Switzerland for distribution in Italy of an innovative test for inflammatory conditions of the intestine, Quantum Blue® Calprotectin. The test which detects calprotectin, a GI inflammatory marker, is a fundamental to... 
 Printer Friendly Version
9/17/2009Meridian Bioscience Granted Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Analytical Sensitivity Claim to the TRU FLU(R) Test Package Insert
CINCINNATI--(BUSINESS WIRE)--Sep. 17, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the company has been granted a Special 510(k) clearance to update the TRU FLU package insert to include analytical sensitivity claims with two strains of 2009 H1N1 virus cultured from positive respiratory specimens. TRU FLU is a rapid test which identifies influenza A and B in human specimens. Meridian’s T... 
 Printer Friendly Version
9/15/2009Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2010 and Reaffirms Fiscal 2009 Guidance
CINCINNATI--(BUSINESS WIRE)--Sep. 15, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2010 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2010, management expects net sales to be in the range of $160 to $165 million and per share diluted earnings to be between $0.90 a... 
 Printer Friendly Version
9/3/2009Meridian Bioscience to Present at the Robert W. Baird 2009 Health Care Conference
CINCINNATI--(BUSINESS WIRE)--Sep. 3, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 1:45 p.m. ET at the Four Seasons Hotel New York. Jack Kraeutler, Chief Executive Officer, and Bill Motto, Executive Chairman of the Board, are scheduled to present. A question and answer session will foll... 
 Printer Friendly Version
7/16/2009Meridian Bioscience Appoints James M. Anderson to Board of Directors
CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has appointed James M. Anderson to its Board of Directors effective immediately. Mr. Anderson is President and Chief Executive Officer of Cincinnati Children’s Hospital Medical Center. His appointment as President and CEO in 1996 followed 20 years of service to the Cincinnati Children’s board of ... 
 Printer Friendly Version
7/16/2009Meridian Bioscience Reports Record Sales and Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2009 Guidance, and Comments on Timing of Fiscal 2010 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record quarterly and nine-month sales of $38.2 million and $105.8 million, respectively, increases of 16% and 3% over the same periods of the prior fiscal year; reported record quarterly and nine-month operating income of $12.5 million and $35.7 million, respectively, increases of 14% and ... 
 Printer Friendly Version
7/7/2009FORTUNE Small Business Again Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies
CINCINNATI--(BUSINESS WIRE)--Jul. 7, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced today that FORTUNE Small Business has ranked Meridian Bioscience, Inc. number 34 on their ninth annual FSB 100 list of the fastest growing small public companies in America. The list appears in the July/August issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2009/. To compile th... 
 Printer Friendly Version
6/10/2009Meridian Bioscience to Present at the William Blair and Company's 29th Annual Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the Company has been invited to present at the William Blair and Company’s 29th Annual Growth Stock Conference on Thursday, June 11 at 9:20 a.m. CDT at the Four Seasons Hotel, Chicago, IL. Jack Kraeutler, Chief Executive Officer, and Bill Motto, Executive Chairman of the Board, are scheduled to present. A question and answer session will f... 
 Printer Friendly Version
6/4/2009Meridian Bioscience Wins GHX 2009 Best in Class Award
CINCINNATI--(BUSINESS WIRE)--Jun. 4, 2009-- Meridian Bioscience (NASDAQ: VIVO) today announced that it is a recipient of a 2009 GHX Best in Class Award for achieving the highest year-over-year market share growth for distributed products in the Microbiology Reagents/Supplies product category for the 2008 calendar year. Meridian Bioscience was among the 30 leading medical-surgical product manufacturers recognized by GHX in five market... 
 Printer Friendly Version
6/3/2009Meridian Bioscience Receives FDA Clearance for New Rapid Campylobacter Test
CINCINNATI--(BUSINESS WIRE)--Jun. 3, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United Stat... 
 Printer Friendly Version
4/16/2009Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Revises Downward Fiscal 2009 Guidance
CINCINNATI, Apr 16, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported second quarter and six months net sales of $33.3 million and $67.6 million, respectively, decreases of 8% and 4% compared to the same periods of the prior fiscal year; reported second quarter and six months operating income of $11.0 million and $23.2 m... 
 Printer Friendly Version
2/4/2009Meridian Bioscience Receives FDA Clearance for New Campylobacter Test
CINCINNATI--(BUSINESS WIRE)-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new test for Campylobacter. Launched as PREMIER™ CAMPY, the rapid EIA test provides for optimized detection of Campylobacter infection, the most commonly diagnosed bacteria for food borne illness in the U.S. Approximately 20 million tests are conducted each year in the U... 
 Printer Friendly Version
1/27/2009Meridian Bioscience Announces Two New Exclusive International Distribution Agreements in Australia and Argentina
CINCINNATI, Jan 27, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the commencement of two new exclusive international distribution agreements. In Australia, Meridian has signed with Immuno Pty, Ltd, based in Sydney. For Argentina, Meridian has signed with Scott Pharma. This decision is consistent with Meridian's stated commitment to expand its non-US businesses. Over the past 25 years Immuno Pty, www.im... 
 Printer Friendly Version
1/22/2009Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2009 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2009--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record first quarter net sales of $34.3 million a 1% increase over the same period of the prior fiscal year; -- reported record first quarter net earnings of $8.1 million, an 8% increase over the same period of the prior fiscal year; -- re... 
 Printer Friendly Version
1/15/2009Meridian Bioscience, Inc. Announces Preliminary First Quarter Operating Results and Revises Fiscal 2009 Revenue Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2009--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that based on preliminary results, it expects revenues for the first quarter of fiscal 2009, ended on December 31, 2008, to be approximately $34,300,000, an increase of 1% over the prior year. During the quarter, sales to our largest distributor were essentially flat. However, shipments to customers from this distributor continued at a ... 
 Printer Friendly Version